Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Behr, Jürgen ^a   Demedts, Maurits ^b   Buhl, Roland ^c   Costabel, Ulrich ^d   Dekhuijzen, Richard P N ^e   Jansen, Henk M ^f   MacNee, William ^g   Thomeer, Michiel ^b   Wallaert, Benoit ^h   Laurent, Francois ⁱ   Nicholson, Andrew G ^j   Verbeken, Eric K ^b   Verschakelen, Johny ^b   Flower, CDR ^k   Petruzzelli, Stefano ^l   De Vuyst, Paul ^m   Bosch, JMM V D ⁿ   Rodriguez Becerra, Eulogio ^o   Lankhorst, Ida ^p   Sardina, Marco ^p   Boissard, Gabrielle ^p   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k Evelyn Hospital   (United Kingdom)

^l UNIVERSITY OF PISA   (Italy)

^m ERASME HOSPITAL   (Belgium)

ⁿ ST ANTONIUS HOSPITAL   (Netherlands)

^o HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^p Zambon Group SpA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; PLACEBO; PREDNISONE; RESPIRATORY TRACT AGENT;

ADULT; AGED; ARTICLE; DESCRIPTIVE RESEARCH; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN TENSION; VITAL CAPACITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; EUROPE; EXERCISE TEST; HOSPITALIZATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ACETYLCYSTEINE; AGED; AZATHIOPRINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; PATIENT DROPOUTS; PREDNISONE; PULMONARY DIFFUSING CAPACITY; RESPIRATORY SYSTEM AGENTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 73949096392     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-101     Document Type: Article

References (25)

1. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
2. Bjoraker JA, Ryu JH, Edwin MH, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199-203.
3. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The clinical significance of reclassifying patients with cryptogenic fibrosing alveolitis according to the histopathological patterns of interstitial pneumonias. Am J Respir Crit Care Med 2000, 162:2213-7.
4. American Thoracic Society Idiopathic pulmonary Fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664. American Thoracic Society.
5. American Thoracic Society ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. General principes and recommendations. Am J Respir Crit Care Med 2002, 165:277-304. American Thoracic Society.
6. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001, 345:517-25. 10.1056/NEJMra003200, 11519507.
7. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen H, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson A, Verbeken E, Verschakelen J, Flower C, Capron F, Petruzzelli S, De Vuyst P, Bosch J, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M, . IFIGENIA Study Group High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353(21):2229-2242. 10.1056/NEJMoa042976, 16306520, IFIGENIA Study Group.
8. Behr J, Maier K, Degenholb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997, 156:1897-901.
9. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2285-2287. 10.1056/NEJMe058210, 16306527.
10. Wells AU, Desai SR, Rubens MB, Goh N, Cramer D, Nicholson A, Colby T, du Bois R, Hansell D. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167:962-969. 10.1164/rccm.2111053, 12663338.
11. Official Statement of the European Respiratory Society Standardized lung function testing. Eur Respir J 1993, 6:5-100. Official Statement of the European Respiratory Society.
12. Roca J, Whipp B. ERS Task Force on Standardization of Clinical Exercise Testing. Clinical exercise testing with reference to lung disease: indications, standardization and interpretation strategies. Eur Respir J 1997, 10:2662-89. 10.1183/09031936.97.10112662, 9426113.
13. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolapopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-7. 10.1164/rccm.200210-1245OC, 12791580.
14. Watters L, King TE, Schwarz M, Waldron JA, Stanford R, Cherniak R. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986, 133:97-103.
15. King T, Tooze J, Schwartz M, Brown K, Cherniack R. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respi Crit Care Med 2001, 164:1171-1181.
16. Gay SE, Kazerooni EA, Toews GB, Lynch J, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R, Martinez FJ. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063-72.
17. Raghu G, Brown K, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo controlled trial of interferon gamma-1β in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350:125-33. 10.1056/NEJMoa030511, 14711911.
18. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD- 1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81. 10.1164/rccm.200705-732OC, 17901413.
19. Collard HR, King TE, Bucher Bartelson B, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-42. 10.1164/rccm.200211-1311OC, 12773325.
20. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, Martinez FJ. Prognostic implications of physiologic and radio-graphic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543-8. 10.1164/rccm.200209-1112OC, 12773329.
21. Flaherty K, Andrei A, Murray S, Fraley C, Colby T, Travis W, Lama V, Kazerooni E, Gross B, Toews G, Martinez F. Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test. Am J Respir Crit Care Med 2006, 174(7):803-9. 10.1164/rccm.200604-488OC, 2648064, 16825656.
22. Martinez F, Safrin S, Weycker D, Starko K, Bradford W, King T, Flaherty K, Schwartz D, Noble P, Raghu G, Brown K, . IPF Study Group The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142:963-967. IPF Study Group.
23. Wells AU. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur Respir J 2006, 27:664-666. 10.1183/09031936.06.00010006, 16585071.
24. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008, 31:1357-1367. 10.1183/09031936.00171307, 18515559.
25. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML, , . British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standard of Care Committee, Thoracic Society of Australia, New Zealand Thoracic Society, Irish Thoracic Society Interstitial lung disease guideline. Thorax 2008, 63(Suppl 5):v1-58. British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standard of Care Committee, Thoracic Society of Australia, New Zealand Thoracic Society, Irish Thoracic Society.